BNTX BNTX
Company Profile ↓Company Overview
BNTX (BNTX) is a publicly traded company listed on with a market capitalization of $23.88B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $2.87B (+4.3% YoY); net profit $-1.14B.
- Trailing 12 Months Year-on-year growth — revenue +4.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -45.1%, profit CAGR -37.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -45.06% |
| 1 Year: | 4.32% |
Compounded Profit Growth
| 5 Years: | -37.35% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -17.18% |
| 6 Months: | -14.85% |
| 3 Months: | -3.48% |
| 1 Month: | -2.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -45.1% CAGR over 5 years.
- Earnings shrank at -37.3% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 182.80M | 260.80M | 1.52B | 907.40M | 118.10M |
| Cost of Revenue | - | 83.80M | 76.40M | 148.30M | 333.30M | 71.40M |
| Gross Profit | - | 99.00M | 184.40M | 1.37B | 574.10M | 46.70M |
| Operating Expenses | - | 660.50M | 662.90M | 716.70M | 854.60M | 717.90M |
| Operating Income | - | -561.50M | -478.50M | 653.90M | -280.50M | -671.20M |
| EBITDA | - | -398.90M | -348.30M | 778.10M | -511.60M | -442.80M |
| Interest Expense | -2.20M | 3.70M | 3.40M | - | - | 4.00M |
| Pretax Income | - | -445.40M | -402.70M | 24.70M | -227.40M | -568.10M |
| Tax Provision | - | -29.60M | -16.10M | 53.40M | 77.60M | -36.20M |
| Net Income | - | -415.80M | -386.60M | -28.70M | -305.00M | -531.90M |
| Diluted EPS | - | -1.73 | -1.60 | -0.12 | -1.25 | -2.10 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 17.31B | 3.82B | 2.75B | 2.87B |
| Cost of Revenue | - | 3.00B | 599.80M | 541.30M | 641.80M |
| Gross Profit | - | 14.32B | 3.22B | 2.21B | 2.23B |
| Operating Expenses | - | 2.01B | 2.34B | 2.92B | 2.87B |
| Operating Income | - | 12.30B | 875.60M | -709.40M | -640.70M |
| EBITDA | - | 13.10B | 1.38B | -362.80M | -653.80M |
| Interest Expense | - | 18.90M | 7.50M | 16.90M | 14.20M |
| Pretax Income | - | 12.95B | 1.19B | -677.70M | -1.05B |
| Tax Provision | - | 3.52B | 255.80M | -12.40M | 85.30M |
| Net Income | - | 9.43B | 930.30M | -665.30M | -1.14B |
| Diluted EPS | - | 37.77 | 3.83 | -2.77 | -4.70 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.28B | 23.01B | 22.53B | 21.99B |
| Current Assets | - | 21.92B | 19.53B | 18.80B | 16.15B |
| Cash & Equivalents | - | 13.88B | 11.66B | 9.76B | 7.68B |
| Inventory | - | 439.60M | 357.70M | 283.30M | 110.70M |
| Receivables | - | 7.15B | 2.16B | 1.46B | 924.20M |
| Total Liabilities | - | 3.22B | 2.76B | 3.12B | 2.76B |
| Current Liabilities | - | 2.95B | 2.07B | 2.52B | 2.14B |
| Long Term Debt | - | 176.20M | 191.00M | 214.70M | 215.20M |
| Total Debt | - | 212.20M | 219.10M | 254.20M | 267.40M |
| Total Equity | - | 20.06B | 20.25B | 19.41B | 19.22B |
| Shares Outstanding | - | 248.55M | 248.55M | 248.55M | 259.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 13.58B | 5.37B | 207.70M | 456.00M |
| Investing Cash Flow | - | -35.30M | -6.95B | -2.08B | -2.47B |
| Financing Cash Flow | - | -1.42B | -778.60M | -45.90M | -52.90M |
| Capital Expenditure | - | -363.30M | -705.50M | -452.30M | -749.00M |
| Free Cash Flow | - | 13.21B | 4.67B | -244.60M | -293.00M |
| Net Change in Cash | - | 12.12B | -2.36B | -1.92B | -2.07B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 82.7% | 84.3% | 80.3% | 77.6% |
| Operating Margin % | - | 71.1% | 22.9% | -25.8% | -22.3% |
| Net Margin % | - | 54.5% | 24.4% | -24.2% | -39.6% |
| ROE % | - | 47.0% | 4.6% | -3.4% | -5.9% |
| ROCE % | - | 60.5% | 4.2% | -3.5% | -3.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNTX
BioNTech (NasdaqGS:BNTX) Stock Faces Widening Losses Despite Deeper Oncology Pipeline - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNMk1mSV96TFN4ZWhqYld3M0V4b1N4dUZQYVN6QjJnT1h3NkJCY1MtQmRnZnZqcG9IWFlycGw3aXNqemdObk9PTk9qemZPNXg1VncxQnRSXzk1bThsZzBBSW13ZUhWRTBoVU5pSG43bHBnRFc3aEVhX01iMS1TeW9oN1F3RHNYTUIxcEZDOU…
BIONTECH SE ($BNTX) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPcVduS1FkYU92UDVBcmo4VXZSTnhlNjR0Xzh2bTk3S296SVRncU12TkpqZTducXc0cTJEVWR3N1oyS3BYNWhKY1BJRUlPQkNYZzhkOFZldFJOb1dFdFc0M0lvazVNSS0xWTNPc1Jydl8tUkZSWjI3WW4tdElSM1Z5ay1rbXhncnBzWC1wVw…
BioNTech appoints CEO with 14 pivotal oncology trials underway - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQdVNLN3dUZUpGa3dBNTN5alctQm92eUVoazVHcktFN3B1MnU5S0VUUElnUXJJMWJVMUFNZzUxazRSdWhiRlJBQlotNXNBNE56WkZKQWJ6dzdLbExuZkR0bURSS2toT1RyYy1HcmFJa3FnbWY0ejB5bERWd1U1VXFJZE90SHlyMVhCcTNQZ1…
BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPbF9SNlpZbE9xQ0xkcG5oVl8yYVFVYXBCcXBHbkt2U3RZRHNndnFIZlpqdWx3M2RYUEhUSllBdWJScDBaQU15MzVJY1dwc21VdGphdm5vYUc1TjFwZmhMb3dIUV9aZ3BrRHZlcmY1OHR5UGh4aDVEVnAtaDV0TVo4TWp0cFA2bGhVOUF4NE…
BNTX Looks 8.5% Overvalued on GF Value™ - GuruFocus
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQNFExeXZPNFo3ZlRUVXhiVi1EMlhNY0dzY1Foa2xXRlRIdDdobWtYR3VaT0ljQml0anVRRTBxYjBxOWpqYjNhY1BjQkNJNHhPR1QtTUE5T08zY1dxeE91NEtBNFFiaGpfVWxVdTZIZHY5ZzRjVkdGOUUyYnQydkVUSw?oc=5" target="_…
BioNTech: The Market Is Offering A 17-Program Oncology Pipeline For Almost Free (BNTX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOWcxM0pQeEV4eEFFOXFzUjNkblN6SWJVbTBxMVFLMGZlMlhVRjFfRTF0YTRMVS1DMVFIS2g0NUV1clMzNlJzdkhsajh4OVByRGxIeTFPNlJnMnd2UkJvQ1ljVEpwcEs0UHVUTEpMa29NVm9LdGtTVFJsa2hqZTJRZE9XSFAxaVY0SkJjUV…
BNTX — Frequently Asked Questions
What is the current share price of BNTX?
As of 2026-08-05 17:25 PDT, BNTX trades at $92.18 on NASDAQ/NYSE. Its 52-week range is $83.89 to $119.34.
What is the market capitalisation of BNTX?
BNTX has a market capitalisation of $23.88B on NASDAQ/NYSE.
What is the P/E ratio of BNTX?
BNTX trades at a trailing price-to-earnings (P/E) ratio of -19.61. Its price-to-book (P/B) ratio is 1.24.
What is the return on equity (ROE) of BNTX?
BNTX has a return on equity (ROE) of -5.91%. Its return on capital employed (ROCE) is -5.22%.
Is BNTX a good stock to buy?
This page provides a data-driven analysis of BNTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.